Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-09-11
2007-09-11
Salimi, Ali R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C424S009100, C514S649000
Reexamination Certificate
active
10277413
ABSTRACT:
A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P450metabolism, wherein the methylphenidate is d-threo-methylphenidate.
REFERENCES:
patent: 2407631 (1946-09-01), Hartmann et al.
patent: 2838519 (1958-06-01), Rometsch
patent: 2957880 (1960-10-01), Rometsch
patent: 4192827 (1980-03-01), Mueller et al.
patent: 5583140 (1996-12-01), Bencherif et al.
patent: 5733756 (1998-03-01), Zeitlin et al.
patent: 5874090 (1999-02-01), Baker et al.
patent: 5908850 (1999-06-01), Zeitlin et al.
patent: 5922736 (1999-07-01), Dariani et al.
patent: 6255325 (2001-07-01), Dariani et al.
patent: 6355656 (2002-03-01), Zeitlin et al.
patent: 6486177 (2002-11-01), Zeldis et al.
patent: 6531489 (2003-03-01), Harris et al.
Aoyama, T. et al. “Pharmacokinetics and Pharmacodynamics of (+)-threo-Methylphenidate Enantiomer in Patients with Hypersomnia”Clinical Pharmacology&Therapeutics, 1994, pp. 270-276, vol. 55, No. 3.
Ariens, E. J. “Stereoselectivity in Pharmacodynamics and Pharmacokinetics”Schweiz. Med. Wochenschr., 1990, pp. 131-134, vol. 120, No. 5.
Ariens, E. J. “Racemic Therapeutics-Ethical and Regulatory Aspects”Eur. J. Clin. Pharmacol., 1991, pp. 89-93, vol. 41.
Drimmer, E. J. et al., “Desipramine and Methylphenidate Combination Treatment for Depression: Case Report”Am. J. Psychiatry, 1983, pp. 241-242, vol. 140, No. 2, **abstract only.
Eckerman, D. A. et al. “Enantioselective Behavioral Effects of threo-Methylphenidate in Rats”Pharmacology Biochemistry&Behavior, 1991, pp. 875-880, vol. 40, No. 4.
Grob, C. S. et al. “Suspected Adverse Methylphenidate-impipramine Interactions in Children”J. Dev. Behav. Pediatr., 1986, pp. 265-267, vol. 7, No. 4, **abstract only.
Licamele, W. L. et al. “The Concurrent Use of Lithium and Methylphenidate in a Child”J. Am. Acad. Child Adolesc. Psychiatry, 1989, pp. 785-787, vol. 28, No. 5, **abstract only.
Patrick, K. S. et al. “Pharmacology of the Enantiomers of the threo-Methylphenidate”The Journal of Pharmacology and Experimental Therapeutics, 1987, pp. 152-158, vol. 241, No. 1.
Rapport, M. D. et al. “Methylphenidate and Desipramine in Hospitalized Children: I. Separate and Combined Effects on Cognitive Function”J. Am. Acad. Child. Adolesc. Psychiatry, 1993, pp. 333-342, vol. 32, No. 2, **abstract only.
Tyndale, R. F. et al. “Neuronal Cytochrome P450IID1 (Debrisoquine/Sparteine-Type): Potent Inhibition of Activity by (-)-Cocaine and Nucleotide Sequence Identity to Human Hepatic P450 Gene CYP2D”Molecular Pharmacology, An International Journal, 1991, pp. 63-68, vol. 40, No. 1.
Aoyama, T. et al. “Nonlinear kinetics of threo-methylphenidate enantiomers ina patient with narcolepsy and in healthy volunteers”Eur. J. Clin. Pharmacol, 1993, pp. 79-84, vol. 44.
Barnes, N. M. et al. “THe interaction of R(+)-and S(−)-zacopride with PCPA to modify rodent aversive behaviour”European Journal of Pharmacology, 1992, pp. 15-25, vol. 218.
Ding, Y.-S. et al. “Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain”Psychopharmacology, 1997, pp. 71-78, vol. 131.
Hubbard, J. W. et al. “Enantioselective Aspects of the Disposition of dl-threo-Methylphenidate after the administration of a sustained-release formulation to children with attention deficit-hyperactivity disorder”Journal of Pharmaceutical Sciences, 1989, pp. 944-947, vol. 78, No. 11.
Srinivas, N. R. et al. “Enantioselective pharmacokinetics and pharmacodynamics of dl-threo-methylphenidate in children with attention deficit hyperactivity disorder”Clin. Pharmacol. Ther., 1992, pp. 561-568, vol. 52, No. 5.
Srinivas, N. R. et al. “Enantioselective Pharmacokinetics of dl-threo-Methylphenidate in Humans”Pharmaceutical Research, 1993, pp. 14-21, vol. 10, No. 1.
McGlashan Richards Andrew John
Pope Nicholas Robert
Celltech Pharma Europe Limited
Salimi Ali R.
Saliwanchik Lloyd & Saliwanchik
LandOfFree
Composition comprising methylphenidate and another drug does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition comprising methylphenidate and another drug, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition comprising methylphenidate and another drug will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788234